Surrogate endpoints for overall survival in digestive oncology trials: Which candidates? A questionnaires survey among clinicians and methodologists

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Methy, Nicolas ^a   Bedenne, Laurent ^a   Bonnetain, Franck ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b EA 4184   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; HUMAN; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; TUMOR LOCALIZATION; VALIDATION PROCESS; BIOASSAY; CLINICAL TRIAL; DIGESTIVE SYSTEM TUMOR; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; FRANCE; METHODOLOGY; MORTALITY; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS; SURVIVAL; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIGESTIVE SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; FRANCE; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953243023     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-277     Document Type: Article

References (37)

1. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008, 13(Suppl 2):19-21. 10.1634/theoncologist.13-S2-19, 18434634.
2. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 2004, 15(4):545-549. 10.1093/annonc/mdh127, 15033657.
3. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95. 10.1067/mcp.2001.113989, 11240971, Biomarkers Definitions Working Group.
4. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006, 25(2):183-203. 10.1002/sim.2319, 16252272.
5. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 2009, 14(2):102-111. 10.1007/s10147-009-0885-4, 19390940.
6. Methy N, Bedenne L, Conroy T, Bouche O, Chapet O, Ducreux M, Gerard JP, Bonnetain F. Surrogate endpoints in neoadjuvant rectal cancer trials: Statistical evaluation using data from the FFCD 9203 trial. Ann Oncol 2009, 21(3):518-524. 10.1093/annonc/mdp340, 19759186.
7. Methy N, Bedenne L, Bonnetain F. [Validation of surrogate endpoints in digestive oncology]. Bull Cancer 2009, 96(5):591-595.
8. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005, 23(34):8664-8670. 10.1200/JCO.2005.01.6071, 16260700.
9. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007, 25(29):4569-4574. 10.1200/JCO.2006.10.4323, 17876008.
10. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007, 25(29):4562-4568. 10.1200/JCO.2006.08.1935, 17876010.
11. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25(33):5218-5224. 10.1200/JCO.2007.11.8836, 18024867.
12. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000, 32(4):1008-1015. 10.1046/j.1365-2648.2000.01567.x, 11095242.
13. Kassaï B, Gueyffier F, Boissel JP. Critères intermédiaires et critères de substitution. Médecine Thérapeutique 2006, 12(2):96-103.
14. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8(4):431-440. 10.1002/sim.4780080407, 2727467.
15. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356(9227):373-378. 10.1016/S0140-6736(00)02528-9, 10972369.
16. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006, 7(9):741-746. 10.1016/S1470-2045(06)70800-2, 16945769.
17. Burzykowski T, Bang Y, . on behalf of the GASTRIC project. Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol 2009, 27(15S suppl):abstr 4517. on behalf of the GASTRIC project. .
18. Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006, 42(10):1344-1350. 10.1016/j.ejca.2006.02.011, 16730974.
19. Collette L. Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials. Eur Urol 2008, 53(1):6-9. 10.1016/j.eururo.2007.08.041, 17764823.
20. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 1996, 125(7):605-613.
21. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003, 21(7):1404-1411. 10.1200/JCO.2003.08.072, 12663734.
22. Apolone G, Joppi R, Bertele V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005, 93(5):504-509. 10.1038/sj.bjc.6602750, 2361592, 16136026.
23. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005, 24(1):67-78. 10.1377/hlthaff.24.1.67, 15647217.
24. Carroll K, Ross HC, Evans D, France L, Hemmings R, Hughes S, Lynn F, Mahoney P, Phillips A. Conditional approval: discussion points from the PSI conditional approval expert group. Pharm Stat 2008, 7(4):263-269. 10.1002/pst.309, 17847030.
25. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009, 27(17):2874-2880. 10.1200/JCO.2008.20.4107, 2698020, 19414672.
26. Perrone F. Don't forget survival, please. Lancet Oncol 2006, 7(9):703-704. 10.1016/S1470-2045(06)70839-7, 16945763.
27. Abrams J. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: a commentary. J Clin Oncol 2005, 23(34):8564-8565. 10.1200/JCO.2005.03.6186, 16260691.
28. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res 2008, 17(5):529-535. 10.1177/0962280207081853, 18285442.
29. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008, 26(22):3721-3726. 10.1200/JCO.2007.14.1192, 18669458.
30. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100(10):698-711. 10.1093/jnci/djn134, 18477802.
31. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007, 99(13):998-1003. 10.1093/jnci/djm024, 17596575.
32. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007, 25(24):3572-3575. 10.1200/JCO.2007.12.1368, 17704403.
33. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010, 21(1):7-12. 10.1093/annonc/mdp523, 19901012.
34. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. 10.1200/JCO.2006.06.7629, 17008704.
35. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-1123. 10.1056/NEJMoa060829, 16971718.
36. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 1996, (20):7-9.
37. Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998, 16(11):3662-3673.